Skip to content

CELU

Celularity Inc

NASDAQ · Healthcare · Biotechnology · US

$0.81
−1.02%
Ask drillr

Year over year

Reported trailing growth

Revenue
-58.1%
EBITDA
+35.7%
EBIT
-4.6%
EPS
+43.8%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+13.9%
EBITDA
-77.7%
EBIT
-59.8%
Net income
-58.4%
EPS
-35.7%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026